Who We Are

Mirum is a Latin word that means extraordinary, amazing or remarkable. We chose Mirum as our company name because it speaks to the impact we hope we can make for patients and their families.

1

2

3

4

5

6

About Mirum

Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. We are advancing our lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families.

If left untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases.

Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.

Leadership

Mirum has assembled some of the world’s top experts in liver disease and pharmaceutical development with significant experience in liver and rare diseases and progressing products from early stage research to clinical trials and ultimately to regulatory approval and commercialization.

Mike Grey

June 19, 2019

Executive Chairman

Michael Grey has served as executive chairman since March 2019 and is a co-founder of Mirum. Mike previously served as chief executive officer from the company’s inception in May 2018 to March 2019. Mr. Grey has served as executive chairman of Amplyx Pharmaceuticals, Inc. since

Chris Peetz

June 19, 2019

President & Chief Executive Officer

Chris Peetz is a co-founder of Mirum and has served as president since December 2018 and as chief executive officer since March 2019. Chris has been an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. Prior to joining Mirum, Chris served as the chief executive officer of

Ian Clements, Ph.D.

June 19, 2019

Senior Vice President, Finance & Communications

Ian Clements, Ph.D., has served as senior vice president finance and communications and our principal financial and accounting officer since March 2019. Prior to joining Mirum, Ian served as vice president of investor relations at Dermira, Inc. from

Thomas Jaecklin, M.D.

June 19, 2019

Senior Vice President, Clinical Development

Thomas Jaecklin, M.D., is senior vice president of clinical development and the medical lead of the pediatric cholestasis development program at Mirum Pharmaceuticals. Thomas brings 20 years of academic and industry experience in

Lara Longpre

June 19, 2019

Chief Development Officer

Lara Longpre is the chief development officer for Mirum Pharmaceuticals, where she leads development operations, program management and alliance management. Lara brings to Mirum more than 25 years of experience developing

Bernard Parker

June 19, 2019

Senior Vice President, Global Commercialization

Bernard Parker is senior vice president, global commercialization at Mirum Pharmaceuticals, where he leads the company’s commercialization strategy and global launch planning. Bernard brings more than 20 years of commercialization, corporate development and

Pamela Vig, Ph.D.

June 19, 2019

Chief Scientific Officer

Pamela Vig, Ph.D., is chief scientific officer for Mirum Pharmaceuticals, where she leads scientific and clinical aspects of drug development. Pam brings 25 years of industry experience in clinical development, medical affairs and

Ed Tucker, M.D.

November 4, 2019

Chief Medical Officer

Ed Tucker, M.D., is chief medical officer at Mirum Pharmaceuticals. Dr. Tucker most recently served as chief operating officer at Acerta Pharma LLC where he was responsible for business and operational activities across the heme-oncology pipeline.